A function-blocking CD47 antibody suppresses stem cell and EGF signaling in triple-negative breast cancer
Open accessThe DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
// Sukhbir Kaur 1 , Abdel G. Elkahloun 2 , Satya P. Singh 3 , Qing-Rong Chen 4 , Daoud M. Meerzaman 4 , Timothy Song 1 , Nidhi Manu 1 , Weiwei Wu 2 , Poonam Mannan 4 , Susan H. Garfield 5 and David D. Roberts 1 1 Laboratory of Pathology, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA 2 Cancer Genetics and Comparative Genomics Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA 3 Inflammation Biology Section, Laboratory of Molecular Immunology, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, MD, USA 4 Center for Biomedical Informatics and Information Technology, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA 5 Laboratory of Cancer Biology and Genetics, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD, USA Correspondence to: David D. Roberts, email: // Keywords : CD47, cancer stem cells, triple-negative breast cancer, epidermal growth factor receptor, therapeutic antibodies Received : January 15, 2016 Accepted : January 21, 2016 Published : January 31, 2016 Abstract CD47 is a signaling receptor for thrombospondin-1 and the counter-receptor for signal-regulatory protein-α (SIRPα). By inducing inhibitory SIRPα signaling, elevated CD47 expression by some cancers prevents macrophage phagocytosis. The anti-human CD47 antibody B6H12 inhibits tumor growth in several xenograft models, presumably by preventing SIRPα engagement. However, CD47 signaling in nontransformed and some malignant cells regulates self-renewal, suggesting that CD47 antibodies may therapeutically target cancer stem cells (CSCs). Treatment of MDA-MB-231 breast CSCs with B6H12 decreased proliferation and asymmetric cell division. Similar effects were observed in T47D CSCs but not in MCF7 breast carcinoma or MCF10A breast epithelial cells. Gene expression analysis in breast CSCs treated with B6H12 showed decreased expression of epidermal growth factor receptor (EGFR) and the stem cell transcription factor KLF4. EGFR and KLF4 mRNAs are known targets of microRNA-7, and B6H12 treatment correspondingly enhanced microRNA-7 expression in breast CSCs. B6H12 treatment also acutely inhibited EGF-induced EGFR tyrosine phosphorylation. Expression of B6H12-responsive genes correlated with CD47 mRNA expression in human breast cancers, suggesting that the CD47 signaling pathways identified in breast CSCs are functional in vivo . These data reveal a novel SIRPα-independent mechanism by which therapeutic CD47 antibodies could control tumor growth by autonomously forcing differentiation of CSC.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Subramanian, A., Tamayo, P., Mootha, V. K., Mukherjee, S., Ebert, B. L., Gillette, M. A., Paulovich, A., Pomeroy, S. L., Golub, T. R., Lander, E. S., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0506580102 · Cited by 53,625
Genes that mediate breast cancer metastasis to the brain
Bos, P. D., Zhang, X. H.-F., Nadal, C., Shu, W., Gomis, R. R., Nguyen, D. X., Minn, A. J., van de Vijver, M. J., Gerald, W. L., Foekens, J. A., et al. (2009) · Nature · doi:10.1038/nature08021 · Cited by 1,863
Zhang, H., Lu, H., Xiang, L., Bullen, J. W., Zhang, C., Samanta, D., Gilkes, D. M., He, J., & Semenza, G. L. (2015) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1520032112 · Cited by 420 · cited 3×
“Consistent with previous reports of elevated CD47 in CSC [16-19] CD47 showed 2.”
BackgroundThrombospondin-1 inhibits VEGF receptor-2 signaling by disrupting its association with CD47
Kaur, S., Martin-Manso, G., Pendrak, M. L., Garfield, S. H., Isenberg, J. S., & Roberts, D. D. (2010) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.172304 · Cited by 235
Self-citation
Cited by
The CD47‐SIRPα signaling axis as an innate immune checkpoint in cancer
Matlung, H. L., Szilagyi, K., Barclay, N. A., & van den Berg, T. K. (2017) · Immunological Reviews · doi:10.1111/imr.12527 · Cited by 557
Next generation of immune checkpoint inhibitors and beyond
Marin-Acevedo, J. A., Kimbrough, E. O., & Lou, Y. (2021) · Journal of Hematology & Oncology · doi:10.1186/s13045-021-01056-8 · Cited by 548
The Role of the Extracellular Matrix in Cancer Stemness
Nallanthighal, S., Heiserman, J. P., & Cheon, D.-J. (2019) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2019.00086 · Cited by 344
Functions of Immune Checkpoint Molecules Beyond Immune Evasion
Zhang, Y., & Zheng, J. (2020) · Advances in Experimental Medicine and Biology · doi:10.1007/978-981-15-3266-5_9 · Cited by 260
Chemotherapy-induced senescence, an adaptive mechanism driving resistance and tumor heterogeneity
Guillon, J., Petit, C., Toutain, B., Guette, C., Lelièvre, E., & Coqueret, O. (2019) · Cell Cycle · doi:10.1080/15384101.2019.1652047 · Cited by 102
“In addition, it has also been previously reported that CD47 is expressed in cancer initiating cells [67] and that its targeting inactivates CD44CD24 cancer stem cells.”
BackgroundRegulation of senescence escape by TSP1 and CD47 following chemotherapy treatment
Guillon, J., Petit, C., Moreau, M., Toutain, B., Henry, C., Roché, H., Bonichon-Lamichhane, N., Salmon, J. P., Lemonnier, J., Campone, M., et al. (2019) · Cell Death & Disease · doi:10.1038/s41419-019-1406-7 · Cited by 90
Davis, R. M., Campbell, J. L., Burkitt, S., Qiu, Z., Kang, S., Mehraein, M., Miyasato, D., Salinas, H., Liu, J. T. C., & Zavaleta, C. (2018) · Nanomaterials · doi:10.3390/nano8110953 · Cited by 60
Metadata
- Authors
- Kaur, S., Elkahloun, A. G., Singh, S. P., Chen, Q.-R., Meerzaman, D. M., Song, T., Manu, N., Wu, W., Mannan, P., Garfield, S. H., & Roberts, D. D.
- Venue
- Oncotarget
- Publisher
- Impact Journals, LLC
- Published
- 2016-01-31
- Volume
- 7
- Issue
- 9
- Pages
- 10133-10152
- ISSN
- 1949-2553 (ISSN-L)
- OpenAlex
- W2289935555
- Cited by
- 107
- References
- 4
- FWCI
- 5.38
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.